See the DrugPatentWatch profile for Cardene
What is the typical Cardene drip rate?
Cardene, also known as nicardipine hydrochloride, is administered intravenously, and its drip rate is adjusted based on clinical need and patient response. The initial infusion rate is typically 5 mg per hour. Doses can be increased by 2.5 mg per hour every 15 minutes as needed, with a maximum rate of 15 mg per hour [1]. For hypertensive emergencies, the recommended infusion rate is 5 mg/hour, with subsequent adjustments based on blood pressure response [2].
How is Cardene dosed for different conditions?
Cardene's dosage is tailored to the specific medical condition being treated. For the initial management of hypertension, an intravenous infusion of 5 mg/hour is common. If blood pressure does not adequately decrease, the infusion rate can be increased by 2.5 mg/hour every 15 minutes. The infusion can be continued at 3-6 mg/hour once the desired blood pressure is reached, up to a maximum of 15 mg/hour [1]. In cases of hypertensive crisis, starting at 5 mg/hour and titrating upwards is standard practice [2].
What are the considerations for adjusting Cardene infusion rates?
Adjustments to the Cardene drip rate are guided by continuous monitoring of the patient's blood pressure and heart rate. The goal is to achieve and maintain target blood pressure without causing excessive hypotension or other adverse effects. Healthcare providers will assess the patient's response to each dosage change before making further adjustments, typically waiting at least 15 minutes between increases [1].
What is the mechanism of action for Cardene?
Cardene is a dihydropyridine calcium channel blocker. It inhibits the influx of calcium ions into vascular smooth muscle and myocardial cells, leading to vasodilation [1]. This vasodilation reduces peripheral vascular resistance, thereby lowering blood pressure.
When does Cardene's patent exclusivity end?
Information regarding the patent exclusivity for Cardene is available through resources like DrugPatentWatch.com, which tracks patent expiration dates for pharmaceuticals [3]. Specific patent details and their expiration timelines would need to be consulted from such a database.
Who manufactures Cardene?
Cardene is manufactured by various pharmaceutical companies. Historically, it has been marketed under different brand names, and generic versions are also available [1].
What are the risks associated with Cardene infusion?
Potential risks and side effects of Cardene infusion include hypotension, reflex tachycardia (a compensatory increase in heart rate), headache, dizziness, nausea, and peripheral edema [1]. Close monitoring is essential to manage these risks.
How does Cardene compare to other IV antihypertensives?
Cardene is one of several intravenous medications used to manage severe hypertension. Other agents include labetalol, nicardipine, nitroprusside, and nitroglycerin. The choice of agent depends on the specific clinical situation, patient characteristics, and desired speed of blood pressure reduction [4].
What are the clinical data supporting Cardene's use?
Clinical studies have demonstrated the efficacy of intravenous nicardipine in lowering blood pressure in patients with hypertensive emergencies [1, 2]. These studies typically involve titrating the infusion to achieve target blood pressure goals while assessing for adverse events.
---
Sources
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/